Natsume J, Maeda N, Itomi K, Kidokoro H, Ishihara N, Takada H, Okumura A, Kubota T, Miura K, Aso K, Morikawa T, Kato K, Negoro T, Watanabe K
From the Departments of Pediatrics (J.N., N.M., H.K., N.I., H.T., K.M., T.N.)
From the Departments of Pediatrics (J.N., N.M., H.K., N.I., H.T., K.M., T.N.).
AJNR Am J Neuroradiol. 2014 Aug;35(8):1580-5. doi: 10.3174/ajnr.A3899. Epub 2014 Mar 27.
Developmental and seizure outcomes in patients with cryptogenic West syndrome are variable. Our aim was to clarify the relationship between FDG-PET findings in infancy and long-term seizure and developmental outcome in cryptogenic West syndrome.
From 1991 to 1999, we prospectively performed FDG-PET from the onset of cryptogenic West syndrome in 27 patients. PET was performed at onset and at 10 months of age. In 2012, we evaluated the educational status, psychomotor development, and seizure outcome in 23 of the 27 patients (13-22 years of age). The correlation between PET findings and outcome was evaluated.
At onset, PET showed hypometabolism in 13 patients (57%). The second PET after the initial treatment revealed cortical hypometabolism in 7 patients (30%). While hypometabolism at onset disappeared on the second PET in 9 patients, it was newly revealed in 3 patients on the second PET. In 2012, seven patients had persistent or recurrent seizures. Eight patients had intellectual impairment. The first PET did not correlate with seizure or developmental outcome. Five of 7 patients (71%) with hypometabolism seen on the second PET had persistent or recurrent seizures, while 14 of 16 (88%) patients with normal findings on the second PET were free of seizures. Five of 7 patients (71%) showing hypometabolism on the second PET had intellectual impairment. Thirteen of 16 (81%) patients with normal findings on the second PET showed normal intelligence. A significant correlation was found between the second PET and long-term seizure (P = .01) or developmental outcome (P = .03).
Cortical hypometabolism is not permanent; it changes with clinical symptoms. Hypometabolism after initial treatment predicts long-term seizures and poor developmental outcome.
隐源性韦斯特综合征患者的发育及癫痫发作结局存在差异。我们的目的是阐明婴儿期氟脱氧葡萄糖正电子发射断层扫描(FDG-PET)结果与隐源性韦斯特综合征患者长期癫痫发作及发育结局之间的关系。
1991年至1999年,我们对27例隐源性韦斯特综合征患者自发病起前瞻性地进行了FDG-PET检查。PET检查在发病时及10个月龄时进行。2012年,我们评估了这27例患者中23例(年龄13 - 22岁)的教育状况、精神运动发育及癫痫发作结局。评估了PET结果与结局之间的相关性。
发病时,PET显示13例患者(57%)存在代谢减低。初始治疗后的第二次PET显示7例患者(30%)存在皮质代谢减低。虽然发病时的代谢减低在9例患者的第二次PET上消失,但在3例患者的第二次PET上新出现了代谢减低。2012年,7例患者有持续性或复发性癫痫发作。8例患者有智力障碍。首次PET与癫痫发作或发育结局无相关性。第二次PET显示代谢减低的7例患者中有5例(71%)有持续性或复发性癫痫发作,而第二次PET结果正常的16例患者中有14例(88%)无癫痫发作。第二次PET显示代谢减低的7例患者中有5例(71%)有智力障碍。第二次PET结果正常的16例患者中有13例(81%)智力正常。第二次PET与长期癫痫发作(P = .01)或发育结局(P = .03)之间存在显著相关性。
皮质代谢减低并非永久性的;它随临床症状而变化。初始治疗后的代谢减低预示着长期癫痫发作及不良的发育结局。